Dexmedetomidine for reducing succinylcholine-induced myalgia in patients undergoing electroconvulsive therapy: A clinical trial

Abstract

Background
Succinylcholine is commonly used as a neuromuscular blocker during electroconvulsive
therapy (ECT), but it can induce myalgia in patients. Dexmedetomidine, an alpha-2 adrenergic
agonist, may mitigate this side effect. This study investigates the efficacy of dexmedetomidine
in reducing succinylcholine-induced myalgia in ECT patients.